Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2005 Jun;81(956):376–382. doi: 10.1136/pgmj.2004.025403

Management of chronic hepatitis C

R Lo 1, J Kostman 1
PMCID: PMC1743288  PMID: 15937203

Abstract

Hepatitis C virus (HCV) infection is transmitted primarily through percutaneous exposure to blood, and most infections are associated with injection drug use. Progression to chronic HCV occurs in 55% to 86% of infected people, and persistent infection is a major cause of cirrhosis, end stage liver disease, and hepatocellular carcinoma. The detection of HCV antibodies should be performed initially to screen at risk populations. In those who are seropositive, HCV viraemia should be assessed to determine if chronic HCV is present. The HCV genotype should also be determined, as this is the strongest predictor of response to available treatment. A liver biopsy is very often helpful because it can estimate degree of hepatic fibrosis, identify concurrent diseases that might contribute to hepatic injury, and aid in selection of patients for treatment. The decision to start antiviral therapy should take into account potential contraindications to therapy, patient motivation, severity of disease, age, and HCV genotype. Combination therapy with weekly subcutaneous pegylated interferon and daily oral ribavirin is the standard of care for treating patients with chronic HCV.

Full Text

The Full Text of this article is available as a PDF (96.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adinolfi L. E., Gambardella M., Andreana A., Tripodi M. F., Utili R., Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001 Jun;33(6):1358–1364. doi: 10.1053/jhep.2001.24432. [DOI] [PubMed] [Google Scholar]
  2. Alberti A., Chemello L., Benvegnù L. Natural history of hepatitis C. J Hepatol. 1999;31 (Suppl 1):17–24. doi: 10.1016/s0168-8278(99)80369-9. [DOI] [PubMed] [Google Scholar]
  3. Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494–1500. doi: 10.1056/NEJM198911303212202. [DOI] [PubMed] [Google Scholar]
  4. Alter M. J., Kruszon-Moran D., Nainan O. V., McQuillan G. M., Gao F., Moyer L. A., Kaslow R. A., Margolis H. S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19;341(8):556–562. doi: 10.1056/NEJM199908193410802. [DOI] [PubMed] [Google Scholar]
  5. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug;24(2):289–293. doi: 10.1002/hep.510240201. [DOI] [PubMed] [Google Scholar]
  6. Benhamou Y., Bochet M., Di Martino V., Charlotte F., Azria F., Coutellier A., Vidaud M., Bricaire F., Opolon P., Katlama C. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999 Oct;30(4):1054–1058. doi: 10.1002/hep.510300409. [DOI] [PubMed] [Google Scholar]
  7. Booth J. C., O'Grady J., Neuberger J., Thr Royal College of Physicians of London and the British Society of Gastroenterology Clinical guidelines on the management of hepatitis C. Gut. 2001 Jul;49 (Suppl 1):I1–21. doi: 10.1136/gut.49.suppl_1.I1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bruno S., Silini E., Crosignani A., Borzio F., Leandro G., Bono F., Asti M., Rossi S., Larghi A., Cerino A. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997 Mar;25(3):754–758. doi: 10.1002/hep.510250344. [DOI] [PubMed] [Google Scholar]
  9. Cassani F., Cataleta M., Valentini P., Muratori P., Giostra F., Francesconi R., Muratori L., Lenzi M., Bianchi G., Zauli D. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997 Sep;26(3):561–566. doi: 10.1002/hep.510260305. [DOI] [PubMed] [Google Scholar]
  10. Castéra L., Hézode C., Roudot-Thoraval F., Bastie A., Zafrani E-S, Pawlotsky J-M, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003 Feb;52(2):288–292. doi: 10.1136/gut.52.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chung Raymond T., Andersen Janet, Volberding Paul, Robbins Gregory K., Liu Tun, Sherman Kenneth E., Peters Marion G., Koziel Margaret J., Bhan Atul K., Alston Beverly. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29;351(5):451–459. doi: 10.1056/NEJMoa032653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Clifford B. D., Donahue D., Smith L., Cable E., Luttig B., Manns M., Bonkovsky H. L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995 Mar;21(3):613–619. [PubMed] [Google Scholar]
  13. Conry-Cantilena C., VanRaden M., Gibble J., Melpolder J., Shakil A. O., Viladomiu L., Cheung L., DiBisceglie A., Hoofnagle J., Shih J. W. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996 Jun 27;334(26):1691–1696. doi: 10.1056/NEJM199606273342602. [DOI] [PubMed] [Google Scholar]
  14. Conte D., Fraquelli M., Prati D., Colucci A., Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000 Mar;31(3):751–755. doi: 10.1002/hep.510310328. [DOI] [PubMed] [Google Scholar]
  15. Corrao G., Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998 Apr;27(4):914–919. doi: 10.1002/hep.510270404. [DOI] [PubMed] [Google Scholar]
  16. Di Martino V., Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M., Matheron S., Le Moing V., Vachon F., Degott C. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001 Dec;34(6):1193–1199. doi: 10.1053/jhep.2001.29201. [DOI] [PubMed] [Google Scholar]
  17. Donato F., Tagger A., Chiesa R., Ribero M. L., Tomasoni V., Fasola M., Gelatti U., Portera G., Boffetta P., Nardi G. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology. 1997 Sep;26(3):579–584. doi: 10.1002/hep.510260308. [DOI] [PubMed] [Google Scholar]
  18. Donato F., Tagger A., Gelatti U., Parrinello G., Boffetta P., Albertini A., Decarli A., Trevisi P., Ribero M. L., Martelli C. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002 Feb 15;155(4):323–331. doi: 10.1093/aje/155.4.323. [DOI] [PubMed] [Google Scholar]
  19. El-Serag Hashem B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002 Nov;36(5 Suppl 1):S74–S83. doi: 10.1053/jhep.2002.36807. [DOI] [PubMed] [Google Scholar]
  20. Feinstone S. M., Kapikian A. Z., Purcell R. H., Alter H. J., Holland P. V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975 Apr 10;292(15):767–770. doi: 10.1056/NEJM197504102921502. [DOI] [PubMed] [Google Scholar]
  21. Flamm S. L., Parker R. A., Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol. 1998 Apr;93(4):597–600. doi: 10.1111/j.1572-0241.1998.171_b.x. [DOI] [PubMed] [Google Scholar]
  22. Fontana Robert J., Hussain Khozema B., Schwartz Steven M., Moyer Cheryl A., Su Grace L., Lok Anna S. F. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol. 2002 Mar;36(3):401–407. doi: 10.1016/s0168-8278(01)00280-x. [DOI] [PubMed] [Google Scholar]
  23. Fried Michael W., Shiffman Mitchell L., Reddy K. Rajender, Smith Coleman, Marinos George, Gonçales Fernando L., Jr, Häussinger Dieter, Diago Moises, Carosi Giampiero, Dhumeaux Daniel. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975–982. doi: 10.1056/NEJMoa020047. [DOI] [PubMed] [Google Scholar]
  24. Garfein R. S., Vlahov D., Galai N., Doherty M. C., Nelson K. E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996 May;86(5):655–661. doi: 10.2105/ajph.86.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gebo Kelly A., Chander Geetanjali, Jenckes Mollie W., Ghanem Khalil G., Herlong H. Franklin, Torbenson Michael S., El-Kamary Samer S., Bass Eric B. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002 Nov;36(5 Suppl 1):S84–S92. doi: 10.1053/jhep.2002.36817. [DOI] [PubMed] [Google Scholar]
  26. Gibb D. M., Goodall R. L., Dunn D. T., Healy M., Neave P., Cafferkey M., Butler K. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000 Sep 9;356(9233):904–907. doi: 10.1016/s0140-6736(00)02681-7. [DOI] [PubMed] [Google Scholar]
  27. Graham C. S., Baden L. R., Yu E., Mrus J. M., Carnie J., Heeren T., Koziel M. J. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001 Jul 6;33(4):562–569. doi: 10.1086/321909. [DOI] [PubMed] [Google Scholar]
  28. Hadziyannis Stephanos J., Sette Hoel, Jr, Morgan Timothy R., Balan Vijayan, Diago Moises, Marcellin Patrick, Ramadori Giuliano, Bodenheimer Henry, Jr, Bernstein David, Rizzetto Mario. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346–355. doi: 10.7326/0003-4819-140-5-200403020-00010. [DOI] [PubMed] [Google Scholar]
  29. Harris D. R., Gonin R., Alter H. J., Wright E. C., Buskell Z. J., Hollinger F. B., Seeff L. B., National Heart, Lung, and Blood Institute Study Group The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med. 2001 Jan 16;134(2):120–124. doi: 10.7326/0003-4819-134-2-200101160-00012. [DOI] [PubMed] [Google Scholar]
  30. Herrine Steven K. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med. 2002 May 21;136(10):747–757. doi: 10.7326/0003-4819-136-10-200205210-00010. [DOI] [PubMed] [Google Scholar]
  31. Hourigan L. F., Macdonald G. A., Purdie D., Whitehall V. H., Shorthouse C., Clouston A., Powell E. E. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999 Apr;29(4):1215–1219. doi: 10.1002/hep.510290401. [DOI] [PubMed] [Google Scholar]
  32. Hu Ke-Qin, Kyulo Namgyal L., Esrailian Eric, Thompson Kevin, Chase Resa, Hillebrand Donald J., Runyon Bruce A. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004 Jan;40(1):147–154. doi: 10.1016/s0168-8278(03)00479-3. [DOI] [PubMed] [Google Scholar]
  33. Ikeda K., Saitoh S., Arase Y., Chayama K., Suzuki Y., Kobayashi M., Tsubota A., Nakamura I., Murashima N., Kumada H. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999 Apr;29(4):1124–1130. doi: 10.1002/hep.510290439. [DOI] [PubMed] [Google Scholar]
  34. Imazeki Fumio, Yokosuka Osamu, Fukai Kenichi, Saisho Hiromitsu. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003 Aug;38(2):493–502. doi: 10.1053/jhep.2003.50329. [DOI] [PubMed] [Google Scholar]
  35. Karnam Umaprasanna S., Reddy K. Rajender. Pegylated interferons. Clin Liver Dis. 2003 Feb;7(1):139–148. doi: 10.1016/s1089-3261(02)00072-7. [DOI] [PubMed] [Google Scholar]
  36. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999 Apr 22;340(16):1228–1233. doi: 10.1056/NEJM199904223401602. [DOI] [PubMed] [Google Scholar]
  37. Ko Y. C., Ho M. S., Chiang T. A., Chang S. J., Chang P. Y. Tattooing as a risk of hepatitis C virus infection. J Med Virol. 1992 Dec;38(4):288–291. doi: 10.1002/jmv.1890380411. [DOI] [PubMed] [Google Scholar]
  38. Krain Alysa, Wisnivesky Juan P., Garland Elizabeth, McGinn Thomas. Prevalence of human immunodeficiency virus testing in patients with hepatitis B and C infection. Mayo Clin Proc. 2004 Jan;79(1):51–56. doi: 10.4065/79.1.51. [DOI] [PubMed] [Google Scholar]
  39. Kumar R. M., Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol. 1998 Aug;29(2):191–197. doi: 10.1016/s0168-8278(98)80003-2. [DOI] [PubMed] [Google Scholar]
  40. Lauer G. M., Walker B. D. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41–52. doi: 10.1056/NEJM200107053450107. [DOI] [PubMed] [Google Scholar]
  41. Liang T. J., Rehermann B., Seeff L. B., Hoofnagle J. H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000 Feb 15;132(4):296–305. doi: 10.7326/0003-4819-132-4-200002150-00008. [DOI] [PubMed] [Google Scholar]
  42. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R., Goodman Z. D., Koury K., Ling M., Albrecht J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958–965. doi: 10.1016/s0140-6736(01)06102-5. [DOI] [PubMed] [Google Scholar]
  43. Marazuela M., García-Buey L., González-Fernández B., García-Monzón C., Arranz A., Borque M. J., Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996 Jun;44(6):635–642. doi: 10.1046/j.1365-2265.1996.751768.x. [DOI] [PubMed] [Google Scholar]
  44. National Institutes of Health National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. 2002 Nov;36(5 Suppl 1):S3–20. doi: 10.1053/jhep.2002.37117. [DOI] [PubMed] [Google Scholar]
  45. Ortiz Vicente, Berenguer Marina, Rayón José M., Carrasco Domingo, Berenguer Joaquin. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002 Sep;97(9):2408–2414. doi: 10.1111/j.1572-0241.2002.05995.x. [DOI] [PubMed] [Google Scholar]
  46. Pariante C. M., Orrù M. G., Baita A., Farci M. G., Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999 Jul 10;354(9173):131–132. doi: 10.1016/S0140-6736(98)04793-X. [DOI] [PubMed] [Google Scholar]
  47. Peters Marion G., Terrault Norah A. Alcohol use and hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S220–S225. doi: 10.1053/jhep.2002.36811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825–832. doi: 10.1016/s0140-6736(96)07642-8. [DOI] [PubMed] [Google Scholar]
  49. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001 May;34(5):730–739. doi: 10.1016/s0168-8278(00)00097-0. [DOI] [PubMed] [Google Scholar]
  50. Poynard Thierry, McHutchison John, Manns Michael, Trepo Christian, Lindsay Karen, Goodman Zachary, Ling Mei-Hsiu, Albrecht Janice. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002 May;122(5):1303–1313. doi: 10.1053/gast.2002.33023. [DOI] [PubMed] [Google Scholar]
  51. Poynard Thierry, Yuen Man-Fung, Ratziu Vlad, Lai Ching Lung. Viral hepatitis C. Lancet. 2003 Dec 20;362(9401):2095–2100. doi: 10.1016/s0140-6736(03)15109-4. [DOI] [PubMed] [Google Scholar]
  52. Pradat Pierre, Alberti Alfredo, Poynard Thierry, Esteban Juan-Ignacio, Weiland Ola, Marcellin Patrick, Badalamenti Salvatore, Trépo Christian. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002 Oct;36(4 Pt 1):973–977. doi: 10.1053/jhep.2002.35530. [DOI] [PubMed] [Google Scholar]
  53. Ragni M. V., Belle S. H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis. 2001 Mar 1;183(7):1112–1115. doi: 10.1086/319273. [DOI] [PubMed] [Google Scholar]
  54. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect. 2002 Oct;4(12):1219–1225. doi: 10.1016/s1286-4579(02)01649-0. [DOI] [PubMed] [Google Scholar]
  55. Rosen H. R. Acquisition of hepatitis C by a conjunctival splash. Am J Infect Control. 1997 Jun;25(3):242–247. doi: 10.1016/s0196-6553(97)90011-0. [DOI] [PubMed] [Google Scholar]
  56. Rosenberg P. M. Hepatitis C: a hepatologist's approach to an infectious disease. Clin Infect Dis. 2001 Oct 10;33(10):1728–1732. doi: 10.1086/323128. [DOI] [PubMed] [Google Scholar]
  57. Saadeh S., Cammell G., Carey W. D., Younossi Z., Barnes D., Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001 Jan;33(1):196–200. doi: 10.1053/jhep.2001.20534. [DOI] [PubMed] [Google Scholar]
  58. Sartori M., La Terra G., Aglietta M., Manzin A., Navino C., Verzetti G. Transmission of hepatitis C via blood splash into conjunctiva. Scand J Infect Dis. 1993;25(2):270–271. doi: 10.3109/00365549309008497. [DOI] [PubMed] [Google Scholar]
  59. Schreiber G. B., Busch M. P., Kleinman S. H., Korelitz J. J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996 Jun 27;334(26):1685–1690. doi: 10.1056/NEJM199606273342601. [DOI] [PubMed] [Google Scholar]
  60. Seeff Leonard B. Natural history of chronic hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S35–S46. doi: 10.1053/jhep.2002.36806. [DOI] [PubMed] [Google Scholar]
  61. Stedman Catherine. Herbal hepatotoxicity. Semin Liver Dis. 2002;22(2):195–206. doi: 10.1055/s-2002-30104. [DOI] [PubMed] [Google Scholar]
  62. Strader Doris B., Wright Teresa, Thomas David L., Seeff Leonard B., American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr;39(4):1147–1171. doi: 10.1002/hep.20119. [DOI] [PubMed] [Google Scholar]
  63. Sulkowski Mark S., Ray Stuart C., Thomas David L. Needlestick transmission of hepatitis C. JAMA. 2002 May 8;287(18):2406–2413. doi: 10.1001/jama.287.18.2406. [DOI] [PubMed] [Google Scholar]
  64. Terrault Norah A. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S99–105. doi: 10.1053/jhep.2002.36797. [DOI] [PubMed] [Google Scholar]
  65. Tokars Jerome I., Frank Mark, Alter Miriam J., Arduino Matthew J. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial. 2002 May-Jun;15(3):162–171. doi: 10.1046/j.1525-139x.2002.00051.x. [DOI] [PubMed] [Google Scholar]
  66. Torriani Francesca J., Rodriguez-Torres Maribel, Rockstroh Jürgen K., Lissen Eduardo, Gonzalez-García Juan, Lazzarin Adriano, Carosi Giampiero, Sasadeusz Joseph, Katlama Christine, Montaner Julio. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438–450. doi: 10.1056/NEJMoa040842. [DOI] [PubMed] [Google Scholar]
  67. Tsai J. F., Jeng J. E., Ho M. S., Chang W. Y., Lin Z. Y., Tsai J. H. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol. 1996 Mar;24(3):271–276. doi: 10.1016/s0168-8278(96)80004-3. [DOI] [PubMed] [Google Scholar]
  68. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G., Ferraro T., Concia E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998 Jan 29;338(5):286–290. doi: 10.1056/NEJM199801293380503. [DOI] [PubMed] [Google Scholar]
  69. Westin Johan, Lagging L. M., Spak F., Aires N., Svensson E., Lindh M., Dhillon A. P., Norkrans G., Wejstål R. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002 May;9(3):235–241. doi: 10.1046/j.1365-2893.2002.00356.x. [DOI] [PubMed] [Google Scholar]
  70. Westin Johan, Nordlinder Hans, Lagging Martin, Norkrans Gunnar, Wejstål Rune. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002 Dec;37(6):837–842. doi: 10.1016/s0168-8278(02)00299-4. [DOI] [PubMed] [Google Scholar]
  71. Wiley T. E., McCarthy M., Breidi L., McCarthy M., Layden T. J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998 Sep;28(3):805–809. doi: 10.1002/hep.510280330. [DOI] [PubMed] [Google Scholar]
  72. Yoshida Haruhiko, Arakawa Yasuyuki, Sata Michio, Nishiguchi Shuhei, Yano Michitami, Fujiyama Shigetoshi, Yamada Gotarou, Yokosuka Osamu, Shiratori Yasushi, Omata Masao. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002 Aug;123(2):483–491. doi: 10.1053/gast.2002.34785. [DOI] [PubMed] [Google Scholar]
  73. Zarski J. P., Bohn B., Bastie A., Pawlotsky J. M., Baud M., Bost-Bezeaux F., Tran van Nhieu J., Seigneurin J. M., Buffet C., Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998 Jan;28(1):27–33. doi: 10.1016/s0168-8278(98)80198-0. [DOI] [PubMed] [Google Scholar]
  74. Zarski Jean-Pierre, Mc Hutchison John, Bronowicki Jean-Pierre, Sturm Nathalie, Garcia-Kennedy Richard, Hodaj Enkelejda, Truta Brenda, Wright Teresa, Gish Robert. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003 Mar;38(3):307–314. doi: 10.1016/s0168-8278(02)00387-2. [DOI] [PubMed] [Google Scholar]
  75. Zignego A. L., Bréchot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol. 1999 Aug;31(2):369–376. doi: 10.1016/s0168-8278(99)80239-6. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES